Figure 1 | Scientific Reports

Figure 1

From: The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms

Figure 1

Effects of different doses of BAY-747, runcaciguat and donepezil on long-term memory acquisition. (A) Treatment with 0.03–1.0 mg/kg BAY-747 enhanced memory performance both compared to virtual zero (independent samples t test) and to vehicle (one-way ANOVA with post-hoc LSD tests). Similarly, the positive control donepezil enhanced memory performance at 1.0 mg/kg. Both BAY-747 and donepezil were administered p.o. (2 ml/kg) at 30 min before T1 in a 24 h interval OLT. (B) Treatment with 0.1–1.0 mg/kg runcaciguat enhanced memory performance both compared to virtual zero and to vehicle, as did the positive control and reference compound donepezil at 1.0 mg/kg. Both runcaciguat and donepezil were administered 30 min before T1 in a 24 h interval OLT to enhance memory acquisition processes. Data are represented as mean + SEM. A difference from virtual zero (0 ± 0.065) is depicted with hashes (independent samples t tests, #P < 0.05; ##P < 0.01). A difference from the vehicle condition is depicted with asterisks (one-way ANOVA, LSD t tests, *P < 0.05; **P < 0.01; ***P < 0.001).

Back to article page